ReviewMolecular biomedicine2026
Organoids: technology refining, current applications and future directions.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Human cardiovascular organoids: Biomedical applications and ethical challenges.American heart journal plus : cardiology research and practice · 2026Review
- Patient-Derived Organoids in Gastrointestinal Disease: Current Applications, Limitations, and Future Perspectives.International journal of molecular sciences · 2026Review
- Advances and prospects of 3D air-liquid interface cultured middle ear epithelial cells and inner ear organoids in otologic diseases.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Organoids are derived from pluripotent stem cells or tissue stem cells, progenitor cells, or differentiated cells from healthy or diseased tissues (e.g., tumors). Numerous organoid engineering strategies have been tested to support the culture, growth, proliferation, differentiation, and maturation of organoids. A variety of organoids and organoid-on-chips have also been constructed to reflect real environments of human and mouse organs. Currently, four major areas of potential application for organoids include disease modeling, anticancer drug screening, drug toxicology testing, and gene/cell therapy. For cancer immunotherapy, immune organoids based on co-culturing human tumor cells have been used as a critical platform for drug screening and targeted therapy. This review summarizes recent advances in organoid culture, lists the methods for constructing organoids and their main applications, and highlights its value as a tool for precise cancer modeling. Given the enormous potential of organoids as an in vitro culture model in cancer treatment, we also discussed organoid-based methods for angiogenesis and immune microenvironment modeling, and analyzed the wide range of applications of immune organoids, such as testing treatment response, exploring mechanisms of drug resistance, optimizing treatment strategies, and guiding drug development. Finally, we attempt to look into the critical challenges and bright prospects for cancer organoid research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.